top of page

Life is Quantum Biology and Clinical Observation of COVID-19 Treatment Feature

Clinical Observation of COVID-19 Treatment Feature

Patients and Methods of Treatment

Patients that had tested positive of Coronavirus by their physicians, hospitals and clinics were given the EMERGENCY D-Virus Plan of Care treatment.

It begins with the use of all dietary supplement products:

ImunStem and Aktiffvate to improve immune system function; then the administration of Anterferron-1, Anterferron-2, LunCov-1, and LunCov-2 are given to flush the system and arrest the development of the COVID-19 symptoms. Treatments are continued to support the elimination of Coronavirus. The COVID-19 patients were screened for their symptoms and for verification of their positive COVID-19 test. COVID-19 patients with mild symptoms were excluded from treatment. Symptom screening included multiple different symptoms and their severity. The COVID-19 patients were called on a daily basis.

A total of fifty-four COVID-19 patients are included with forty-seven COVID-19 patients completing treatment. One COVID-19 patient was treated while receiving intubation at Kaweah Delta Medical Center and was discharged from the hospital twenty-four hours after treatment began. Please note that in this treatment no deaths had occurred and the majority of COVID-19 patients showed dramatic improvement within one to four days of initial treatment. A COVID-19 test was Not-Detected after the treatment. All COVID-19 patients began with moderate to severe symptoms and had tested COVID-19 positive for coronavirus before treatment was allowed.

SUMMARY: Forty-seven COVID-19 patients successfully completed the recommended treatment. Eighty (80%) percent of the patients who successfully completed the ImunStem, Aktiffvate, AnterFeeron-1, and AnterFerron-2, LunCov-1, and LunCov-2 combination treatment were asymptomatic or essentially asymptomatic within nine days of starting the treatment. Nineteen (19%) percent of patients required ten days to twenty-five days of treatment before becoming asymptomatic/essentially asymptomatic.

DEFINITION: Asymptomatic/essentially asymptomatic—The COVID-19 patients were either free of all of their symptoms of the COVID-19 illness, or they might have some residual symptoms consisting of, e.g. mild cough, some persistent abnormal sense of taste/smell, or some residual fatigue/stamina issues. But they felt well enough to return to work if that was such the case (The emphasis here was symptom-guided, not repeat COVID-19 testing).

SYMPTOMS: Symptom screening include multiple symptoms and their severity, i.e. fever of 100.4˚F degrees Fahrenheit or higher (if patients had a thermometer), cough severity/duration, chest pain/tightness, Shortness of Breath (SOB) at rest or with exertion, fatigue, loss of appetite/weight loss, body muscle aches and pains, headaches, nausea, vomiting, diarrhea, nasal or nasal sinus stuffiness, rhinorrhea, sore throat, lassitude (poor desire to do anything), sense of anxiety or doom, confusion, loss of sense of taste and smell, numbness, skin rashes, insomnia, and oxygen saturation (if the patient had a home monitor).

Results and Discussion Fifty-four COVID-19 patients were treated, but seven of them did not complete the recommended treatment and were not tabulated in the final results (several could not be reached by phone, one patient eventually revealed no COVID-19 testing was actually done, one refused to take the dietary supplement products in the order recommended, etc.).

Five of the forty-seven COVID-19 patients were considered severe:

1) First male COVID-19 patient had oxygen saturations between and eighty-eight (88%) percent and ninety-three (93%) percent, respiratory rates sometimes in the thirty’s, sever cough, etc. and he was refusing to go to the hospital. His severe symptoms resolved in four or five days on the Technology/Innovation products.

2) First female COVID-19 patient went to the hospital with pneumonia for nine days after completing six days of the dietary supplement products, but she never required a ventilator. She was in the hospital for only nine days.

3) Second male COVID-19 patient was treated in the hospital for three days requiring 4 L/minute of nasal cannula oxygen. Two days after being released from the hospital, he started the ImunStem and Aktiffvate treatment. Within four days, he was able to decrease and stop oxygen.

4) Third male COVID-19 patient is an 86-year-old man who had been on a ventilator in Kaweah Delta Medical Center for about nine days. He was started on the ImunStem and Aktiffvate and subsequently release from the hospital in twenty-four hours.

5) Second female COVID-19 patient had several recurrences of her COVID-19 symptoms requiring prolonged treatments with the EMERGENCY D-Virus Plan of Care and other dietary supplement products.

EMERGENCY D-Virus Plan of Care treatment resulted in the mitigation of the COVID-19 patient symptoms besides shortening the recovery time from the infection. It is recognized that moderate to severely infected COVID-19 patients generally require two weeks or longer to recover. The COVID-19 patient’s recovery time on ImunStem and Aktiffvate treatment was decreased to only nine days in eighty (80%) percent of them.

Also of remarkable note is the significant decrease in the anxiety and degree of suffering the treated COVID-19 patients experienced when compared to the typical COVID-19 patients. In general with COVID-19 patients, there is often a sense of “doom” and a wonder if it is ever going to end or “will I survive?”. The patients who received the ImunStem and Aktiffvate treatment could feel a noticeable difference in their wellbeing generally within one to two days of starting treatment. This gave them hope and expectancy of their return to health.


For more information: Also read:



bottom of page